SUBSCRIBE
SUBSCRIBE

Moody’s Upgrades Teva Pharmaceutical Industries Limited Rating to A3

January 14, 2010 | 
1 min read
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that Moody's Investor services has upgraded the Company's rating to A3 from Baa1. Following this most recent upgrade, the rating outlook is now stable.
Asia
MORE ON THIS TOPIC
Exploration, Currency,Hiding,Discovery,Searching, Businessman
China
Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market
May 20, 2025
 · 
1 min read
 · 
Annalee Armstrong
Creative poster collage of two business partners having deal financial payment giving money banknote isolated on beige color background.
Cancer
Pfizer Puts $6B on the Line for 3SBio’s PD-1/VEGF Antibody
May 20, 2025
 · 
2 min read
 · 
Tristan Manalac
Roche's tower in Shanghai, China
Manufacturing
Roche Makes $300M China Production Promise After Multibillion US Investment
May 12, 2025
 · 
2 min read
 · 
Tristan Manalac
Workplace conflict Job rivalry, jealousy among colleagues concept, angry coworker fighting by pulling golden crown metaphor of job promotion position.
Cancer
Summit’s Campaign To Conquer Keytruda Nears First Global Phase III Data
May 7, 2025
 · 
5 min read
 · 
Nick Paul Taylor